207 related articles for article (PubMed ID: 22162542)
1. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.
Garg V; Chandorkar G; Farmer HF; Smith F; Alves K; van Heeswijk RP
J Clin Pharmacol; 2012 Oct; 52(10):1566-73. PubMed ID: 22162542
[TBL] [Abstract][Full Text] [Related]
2. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
[TBL] [Abstract][Full Text] [Related]
3. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
4. The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.
Teng R; Butler K
Clin Ther; 2013 Jul; 35(7):1025-37. PubMed ID: 23870610
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and the HCV protease inhibitor telaprevir.
Garg V; van Heeswijk R; Yang Y; Kauffman R; Smith F; Adda N
J Clin Pharmacol; 2012 Oct; 52(10):1574-83. PubMed ID: 22039291
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
7. Proximal Roux-en-Y gastric bypass alters drug absorption pattern but not systemic exposure of CYP3A4 and P-glycoprotein substrates.
Chan LN; Lin YS; Tay-Sontheimer JC; Trawick D; Oelschlager BK; Flum DR; Patton KK; Shen DD; Horn JR
Pharmacotherapy; 2015 Apr; 35(4):361-9. PubMed ID: 25757445
[TBL] [Abstract][Full Text] [Related]
8. Effect of brivaracetam on CYP3A activity, measured by oral midazolam.
Stockis A; Watanabe S; Scheen AJ
J Clin Pharmacol; 2015 May; 55(5):543-8. PubMed ID: 25501671
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
Kirby B; Kharasch ED; Thummel KT; Narang VS; Hoffer CJ; Unadkat JD
J Clin Pharmacol; 2006 Nov; 46(11):1313-9. PubMed ID: 17050796
[TBL] [Abstract][Full Text] [Related]
11. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
12. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
13. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S
J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
Garg V; Chandorkar G; Yang Y; Adda N; McNair L; Alves K; Smith F; van Heeswijk RP
Br J Clin Pharmacol; 2013 Feb; 75(2):431-9. PubMed ID: 22642697
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Johansson S; Read J; Oliver S; Steinberg M; Li Y; Lisbon E; Mathews D; Leese PT; Martin P
Clin Pharmacokinet; 2014 Sep; 53(9):837-47. PubMed ID: 25117183
[TBL] [Abstract][Full Text] [Related]
16. Rapid and simultaneous measurement of midazolam, 1'-hydroxymidazolam and digoxin by liquid chromatography/tandem mass spectrometry: application to an in vivo study to simultaneously measure P-glycoprotein and cytochrome P450 3A activity.
Xue X; Huang M; Xiao H; Qin X; Huang L; Zhong G; Bi H
J Pharm Biomed Anal; 2011 Apr; 55(1):187-93. PubMed ID: 21316177
[TBL] [Abstract][Full Text] [Related]
17. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X
Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566
[TBL] [Abstract][Full Text] [Related]
18. The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.
Paulson SK; Wood-Horrall RN; Hoover R; Quintas M; Lawrence LE; Cammarata SK
Clin Ther; 2017 Jun; 39(6):1182-1190. PubMed ID: 28495029
[TBL] [Abstract][Full Text] [Related]
19. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Lee JE; van Heeswijk R; Alves K; Smith F; Garg V
Antimicrob Agents Chemother; 2011 Oct; 55(10):4569-74. PubMed ID: 21825288
[TBL] [Abstract][Full Text] [Related]
20. The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe.
Ma JD; Nafziger AN; Rhodes G; Liu S; Gartung AM; Bertino JS
J Clin Pharmacol; 2006 Jan; 46(1):103-8. PubMed ID: 16397289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
